Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AZN, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Anifrolumab FDA approved Jul 2021 · Saphnelo |
Systemic Lupus Erythematosus | N/A · NCT07913919 | Recruiting |
| Durvalumab FDA approved May 2017 · Imfinzi |
Non-Small Cell Lung Cancer | Phase 3 · NCT05221840 | Active not recruiting |
| Selumetinib FDA approved Apr 2020 · Koselugo |
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb… | Phase 3 · NCT01933932 | Active not recruiting |
| Eplontersen FDA approved Dec 2023 · Wainua (Autoinjector) |
Transthyretin Amyloid Cardiomyopathy | Phase 3 · NCT06194825 | Active not recruiting |
| Olaparib FDA approved Dec 2014 · Lynparza (discontinued) |
Endometrial Neoplasms | Phase 3 · NCT04269200 | Active not recruiting |
| Baxdrostat FDA approved May 2026 · Baxfendy |
Uncontrolled Hypertension | Phase 3 · NCT06034743 | Completed |
| Benralizumab FDA approved Nov 2017 · Fasenra |
Eosinophilic Granulomatous Vasculitis | Phase 3 · NCT04157348 | Active not recruiting |
| Tezepelumab FDA approved Dec 2021 · Tezspire |
Severe Asthma | Phase 3 · NCT07363642 | Recruiting |
| Tremelimumab FDA approved Oct 2022 · Imjudo |
Combined Hepatocellular and Cholangiocarcinoma | Phase 2 · NCT06855225 | Not yet recruiting |
| Osimertinib FDA approved Nov 2015 · Tagrisso |
Carcinoma | Phase 2 · NCT03778229 | Active not recruiting |
| Lenbelintide | Obesity or Overweight | Phase 3 · NCT07776509 | Recruiting |
| Doxorubicin | Large B-cell Lymphoma | Phase 3 · NCT07911553 | Not yet recruiting |
| Elecoglipron | Obesity | Phase 3 · NCT07775404 | Recruiting |
| FLOT Chemotherapy | Gastric | Phase 3 · NCT07877818 | Recruiting |
| Monalizumab | Non-Small Cell Lung Cancer | Phase 3 · NCT05221840 | Active not recruiting |
| Oleclumab | Non-Small Cell Lung Cancer | Phase 3 · NCT05221840 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not AZN's own candidates): Cyclophosphamide, Docetaxel Anhydrous, Rituximab, Regorafenib, Prednisone, Polatuzumab Vedotin, Lomustine, Mepolizumab, Pembrolizumab, Paclitaxel, Pegfilgrastim, Adjuvant durvalumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AZN holds $8.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AZN files for a raise →
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-06 filed 2026-10-08 |
Sharma Mani |
Award (A) | 2 | $159.80 | 19,291 |
| 2026-09-08 filed 2026-09-11 |
Sharma Mani |
Award (A) | 1 | $162.60 | 19,289 |
| 2026-08-08 filed 2026-09-11 |
Sharma Mani |
Purchase (P) | 20 | $160.57 | 19,288 |
| 2026-08-06 filed 2026-08-07 |
Sharma Mani |
Award (A) | 2 | $163.34 | 19,267 |
| 2026-07-06 filed 2026-07-08 |
Sharma Mani |
Award (A) | 2 | $190.43 | 19,265 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →